Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

AstraZeneca Buys Back 318283 Shares

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/30/2012 | 12:23pm CET

AstraZeneca PLC (>> AstraZeneca plc) said Monday it has purchased 318,283 ordinary shares on April 27 at a price of 2666 pence per share for cancellation.

-Shares at 1005 GMT up 1%, at 2704 pence, valuing the company at GBP34 billion.

-By Mark Shapland, Dow Jones Newswires; +44 207 8429358; mark.shapland@dowjones.com

Stocks mentioned in the article : AstraZeneca plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA PLC
12/03 ASTRAZENECA : Bicycle, AstraZeneca enter into potential $1bn multitarget collabo..
12/01 ASTRAZENECA : Christmas toy appeal to help Macclesfield's needy kids
12/01 INNATE PHARMA : First clinical data for monalizumab as a single agent in cancer ..
12/01 ASTRAZENECA : and Abpro join up on cancer research
11/30 TOP NEWS : Smith & Nephew Taps Former AstraZeneca Executive As CFO
11/29 AstraZeneca eyes local prospects
11/29 ASTRAZENECA : takes latest scientific advances in oncology to major US And Europ..
11/28 ASTRAZENECA : *jpmorgan cuts astrazeneca price target to 4600 pence - 'neutral'
11/25 French cancer specialist Innate Pharma can remain independent, for now - CEO
11/25 LONDON MARKET MIDDAY : Soft European Trade Before Wall Street Half-Day
More news
Sector news : Pharmaceuticals - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/02 ALZHEIMER'S DISEASE : Does THC Hold The Key To A Cure?
11/29 Oramed Vs. Novo Nordisk In Race For Oral GLP-1
11/25 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2016 Update
11/23 What's Wrong With Pharma Stocks May Last A While, But...
11/23 Is AstraZeneca A Buy As It Hits New 52-Week Lows?
Advertisement
Financials ($)
Sales 2016 22 922 M
EBIT 2016 6 663 M
Net income 2016 2 406 M
Debt 2016 11 577 M
Yield 2016 5,38%
P/E ratio 2016 25,49
P/E ratio 2017 23,90
EV / Sales 2016 3,32x
EV / Sales 2017 3,52x
Capitalization 64 588 M
More Financials
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 65,0 $
Spread / Average Target 26%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC-11.62%64 588
JOHNSON & JOHNSON9.00%304 591
PFIZER INC.-2.01%191 942
ROCHE HOLDING LTD.-19.61%188 878
NOVARTIS AG-19.07%178 737
MERCK & CO., INC.15.85%168 544
More Results